Transhumanism – Wikipedia, the free encyclopedia

This article is about the futurist ideology and movement. For the critique of humanism, see posthumanism. For the pattern of seasonal migration, see transhumance.

Transhumanism (abbreviated as H+ or h+) is an international cultural and intellectual movement with an eventual goal of fundamentally transforming the human condition by developing and making widely available technologies to greatly enhance human intellectual, physical, and psychological capacities.[1] Transhumanist thinkers study the potential benefits and dangers of emerging technologies that could overcome fundamental human limitations, as well as study the ethical matters involved in developing and using such technologies. They predict that human beings may eventually be able to transform themselves into beings with such greatly expanded abilities as to merit the label "posthuman".[1]

The contemporary meaning of the term transhumanism was foreshadowed by one of the first professors of futurology, FM-2030, who taught "new concepts of the Human" at The New School in the 1960s, when he began to identify people who adopt technologies, lifestyles and worldviews transitional to "posthumanity" as "transhuman".[2] This hypothesis would lay the intellectual groundwork for the British philosopher Max More to begin articulating the principles of transhumanism as a futurist philosophy in 1990, and organizing in California an intelligentsia that has since grown into the worldwide transhumanist movement.[2][3][4]

Influenced by seminal works of science fiction, the transhumanist vision of a transformed future humanity has attracted many supporters and detractors from a wide range of perspectives.[2] Transhumanism has been characterized by one critic, Francis Fukuyama, as among the world's most dangerous ideas,[5] to which Ronald Bailey countered that it is rather the "movement that epitomizes the most daring, courageous, imaginative, and idealistic aspirations of humanity".[6]

According to Nick Bostrom,[1]transcendentalist impulses have been expressed at least as far back as in the quest for immortality in the Epic of Gilgamesh, as well as historical quests for the Fountain of Youth, Elixir of Life, and other efforts to stave off aging and death.

There is debate about whether the philosophy of Friedrich Nietzsche can be considered an influence on transhumanism despite its exaltation of the "bermensch" (overman), due to its emphasis on self-actualization rather than technological transformation.[1][7][8][9]

The fundamental ideas of transhumanism were first mooted in 1923 by the British geneticist J.B.S. Haldane in his essay Daedalus: Science and the Future, which predicted that great benefits would come from applications of advanced sciences to human biology and that every such advance would first appear to someone as blasphemy or perversion, "indecent and unnatural". In particular, he was interested in the development of the science of eugenics, ectogenesis (creating and sustaining life in an artificial environment) and the application of genetics to improve human characteristics, such as health and intelligence.

His article prompted a spate of academic and popular interest; - J. D. Bernal, a crystallographer at Cambridge, wrote The World, the Flesh and the Devil in 1929, in which he speculated on the prospects of space colonization and radical changes to human bodies and intelligence through bionic implants and cognitive enhancement.[10] These ideas have been common transhumanist themes ever since.[1]

The biologist Julian Huxley is generally regarded as the founder of "transhumanism", coining the term in an article written in 1957:

Up till now human life has generally been, as Hobbes described it, nasty, brutish and short; the great majority of human beings (if they have not already died young) have been afflicted with misery we can justifiably hold the belief that these lands of possibility exist, and that the present limitations and miserable frustrations of our existence could be in large measure surmounted The human species can, if it wishes, transcend itself - not just sporadically, an individual here in one way, an individual there in another way, but in its entirety, as humanity.[11]

The rest is here:

Transhumanism - Wikipedia, the free encyclopedia

Transhuman – Wikipedia, the free encyclopedia

Transhuman or trans-human is an intermediary form between the human and the hypothetical posthuman.[1]

The use of the term "transhuman" goes back to French philosopher Pierre Teilhard de Chardin, who wrote in his 1949 book The Future of Mankind:

Liberty: that is to say, the chance offered to every man (by removing obstacles and placing the appropriate means at his disposal) of 'trans-humanizing' himself by developing his potentialities to the fullest extent.[2]

And in a 1951 unpublished revision of the same book:

In consequence one is the less disposed to reject as unscientific the idea that the critical point of planetary Reflection, the fruit of socialization, far from being a mere spark in the darkness, represents our passage, by Translation or dematerialization, to another sphere of the Universe: not an ending of the ultra-human but its accession to some sort of trans-humanity at the ultimate heart of things.[3]

In 1957 book New Bottles for New Wine, English evolutionary biologist Julian Huxley wrote:

The human species can, if it wishes, transcend itself not just sporadically, an individual here in one way, an individual there in another way, but in its entirety, as humanity. We need a name for this new belief. Perhaps transhumanism will serve: man remaining man, but transcending himself, by realizing new possibilities of and for his human nature. "I believe in transhumanism": once there are enough people who can truly say that, the human species will be on the threshold of a new kind of existence, as different from ours as ours is from that of Peking man. It will at last be consciously fulfilling its real destiny.[4]

One of the first professors of futurology, FM-2030, who taught "new concepts of the Human" at The New School of New York City in the 1960s, used "transhuman" as shorthand for "transitional human". Calling transhumans the "earliest manifestation of new evolutionary beings", FM argued that signs of transhumans included physical and mental augmentations including prostheses, reconstructive surgery, intensive use of telecommunications, a cosmopolitan outlook and a globetrotting lifestyle, androgyny, mediated reproduction (such as in vitro fertilisation), absence of religious beliefs, and a rejection of traditional family values.[5]

FM-2030 used the concept of transhuman as an evolutionary transition, outside the confines of academia, in his contributing final chapter to the 1972 anthology Woman, Year 2000.[6] In the same year, American cryonics pioneer Robert Ettinger contributed to conceptualization of "transhumanity" in his book Man into Superman.[7] In 1982, American Natasha Vita-More authored a statement titled Transhumanist Arts Statement and outlined what she perceived as an emerging transhuman culture.[8]

Many thinkers[which?] as of 2013[update] do not regard FM-2030's characteristics as essential attributes of a transhuman. However, analyzing the possible transitional nature of the human species has been and continues to be of primary interest to anthropologists and philosophers within and outside the intellectual movement of transhumanism.[1]

See more here:

Transhuman - Wikipedia, the free encyclopedia

Transhuman: The Eclipse Phase Player’s Guide by infomorph …

We have exceeded the $14,000 base goal for this Kickstarter and will be producing the book Transhuman, and now we have a few final stretch goals to unlock -- check out below!

Stretch Goal 1: 8 Sample Characters

We will add 8 pages to Transhuman, featuring all new sample characters, each with their own illustration, in the style of those in the Eclipse Phase Core Rulebook and Sunward!

Stretch Goal 2: 8 More!

Transhuman gets 8 more sample characters, for a total of 16!

Stretch Goal 3: Freelancer Raise

All of the freelance contributors to Transhuman -- artists, authors, editors -- are going to get a 15% bonus on their pay for the book!

Stretch Goal 4: Morph Recognition Guide

We'll commission art for all the morphs that we've yet to illustrate, and publish a PDF and Print-on-Demand book, the Morph Recognition Guide, with those illustrations, details about the morphs, game stats, and more!

Stretch Goal 5: Morph Recognition Cards

See the original post here:

Transhuman: The Eclipse Phase Player's Guide by infomorph ...

The Transhuman Cosmic Conscious Evolution Website …

Introduction to the website

Our website was hijacked last month !

See the old version of the website ( Euvolution 1.0 )

Cosmotheism is a religion which positively asserts there is an internal meaning and purpose in life and in the cosmos. There is an essential unity, or consciousness that binds all living beings and all of the inorganic cosmos, as one. And what our true identity is this: we are the cosmos, made self-aware and self-conscious by evolution. Our undeniable human purpose, is to know and to complete ourselves as conscious individuals, and also as a self-aware species, and thereby to co-evolve with the cosmos towards total and universal awareness, and towards the ever-higher perfection of consciousness and being.

Transtopia, Euvolution and Prometheism which are all 3 sister web sites have been described by a member of Better Humans as:

"The Magneto Side of the Transhuman Equation" BetterHumans

We in the Eugenics movement are not interested in competing against Adolph Hitler or Karl Marx for some minuscule little 1,000 year Reich. We are interested in competing with Jesus Christ and Buddha for the destiny of man.

Favored Races Manifesto (PDF) by James L. Hart

We Prometheans are voluntarily coming together to purposefully direct the creation of a new post-human species. A species with higher intellect, creativity, consciousness and love of ones people. A communion of intellect and beauty, for the simple reason that it can be done. This creation is what gives us purpose and meaning. No other justification is required for this program to advance our Promethean species.

Go here to see the original:

The Transhuman Cosmic Conscious Evolution Website ...

Supercomputer – Wikipedia, the free encyclopedia

A supercomputer is a computer at the frontline of contemporary processing capacity particularly speed of calculation.

Supercomputers were introduced in the 1960s, made initially and, for decades, primarily by Seymour Cray at Control Data Corporation (CDC), Cray Research and subsequent companies bearing his name or monogram. While the supercomputers of the 1970s used only a few processors, in the 1990s machines with thousands of processors began to appear and, by the end of the 20th century, massively parallel supercomputers with tens of thousands of "off-the-shelf" processors were the norm.[2][3] As of November 2013[update], China's Tianhe-2 supercomputer is the fastest in the world at 33.86 petaFLOPS.

Systems with massive numbers of processors generally take one of two paths: In one approach (e.g., in distributed computing), a large number of discrete computers (e.g., laptops) distributed across a network (e.g., the internet) devote some or all of their time to solving a common problem; each individual computer (client) receives and completes many small tasks, reporting the results to a central server which integrates the task results from all the clients into the overall solution.[4][5] In another approach, a large number of dedicated processors are placed in close proximity to each other (e.g. in a computer cluster); this saves considerable time moving data around and makes it possible for the processors to work together (rather than on separate tasks), for example in mesh and hypercube architectures.

The use of multi-core processors combined with centralization is an emerging trend; one can think of this as a small cluster (the multicore processor in a smartphone, tablet, laptop, etc.) that both depends upon and contributes to the cloud.[6][7]

Supercomputers play an important role in the field of computational science, and are used for a wide range of computationally intensive tasks in various fields, including quantum mechanics, weather forecasting, climate research, oil and gas exploration, molecular modeling (computing the structures and properties of chemical compounds, biological macromolecules, polymers, and crystals), and physical simulations (such as simulations of the early moments of the universe, airplane and spacecraft aerodynamics, the detonation of nuclear weapons, and nuclear fusion). Throughout their history, they have been essential in the field of cryptanalysis.[8]

The history of supercomputing goes back to the 1960s when a series of computers at Control Data Corporation (CDC) were designed by Seymour Cray to use innovative designs and parallelism to achieve superior computational peak performance.[9] The CDC 6600, released in 1964, is generally considered the first supercomputer.[10][11]

Cray left CDC in 1972 to form his own company.[12] Four years after leaving CDC, Cray delivered the 80MHz Cray 1 in 1976, and it became one of the most successful supercomputers in history.[13][14] The Cray-2 released in 1985 was an 8 processor liquid cooled computer and Fluorinert was pumped through it as it operated. It performed at 1.9 gigaflops and was the world's fastest until 1990.[15]

While the supercomputers of the 1980s used only a few processors, in the 1990s, machines with thousands of processors began to appear both in the United States and in Japan, setting new computational performance records. Fujitsu's Numerical Wind Tunnel supercomputer used 166 vector processors to gain the top spot in 1994 with a peak speed of 1.7 gigaflops per processor.[16][17] The Hitachi SR2201 obtained a peak performance of 600 gigaflops in 1996 by using 2048 processors connected via a fast three dimensional crossbar network.[18][19][20] The Intel Paragon could have 1000 to 4000 Intel i860 processors in various configurations, and was ranked the fastest in the world in 1993. The Paragon was a MIMD machine which connected processors via a high speed two dimensional mesh, allowing processes to execute on separate nodes; communicating via the Message Passing Interface.[21]

Approaches to supercomputer architecture have taken dramatic turns since the earliest systems were introduced in the 1960s. Early supercomputer architectures pioneered by Seymour Cray relied on compact innovative designs and local parallelism to achieve superior computational peak performance.[9] However, in time the demand for increased computational power ushered in the age of massively parallel systems.

While the supercomputers of the 1970s used only a few processors, in the 1990s, machines with thousands of processors began to appear and by the end of the 20th century, massively parallel supercomputers with tens of thousands of "off-the-shelf" processors were the norm. Supercomputers of the 21st century can use over 100,000 processors (some being graphic units) connected by fast connections.[2][3]

See the original post:

Supercomputer - Wikipedia, the free encyclopedia

Blue Gene – Wikipedia, the free encyclopedia

Blue Gene is an IBM project aimed at designing supercomputers that can reach operating speeds in the PFLOPS (petaFLOPS) range, with low power consumption.

The project created three generations of supercomputers, Blue Gene/L, Blue Gene/P, and Blue Gene/Q. Blue Gene systems have often led the TOP500[1] and Green500[2] rankings of the most powerful and most power efficient supercomputers, respectively. Blue Gene systems have also consistently scored top positions in the Graph500 list.[3] The project was awarded the 2009 National Medal of Technology and Innovation.[4]

In December 1999, IBM announced a US$100 million research initiative for a five-year effort to build a massively parallel computer, to be applied to the study of biomolecular phenomena such as protein folding.[5] The project had two main goals: to advance our understanding of the mechanisms behind protein folding via large-scale simulation, and to explore novel ideas in massively parallel machine architecture and software. Major areas of investigation included: how to use this novel platform to effectively meet its scientific goals, how to make such massively parallel machines more usable, and how to achieve performance targets at a reasonable cost, through novel machine architectures. The initial design for Blue Gene was based on an early version of the Cyclops64 architecture, designed by Monty Denneau. The initial research and development work was pursued at IBM T.J. Watson Research Center.

At IBM, Alan Gara started working on an extension of the QCDOC architecture into a more general-purpose supercomputer: The 4D nearest-neighbor interconnection network was replaced by a network supporting routing of messages from any node to any other; and a parallel I/O subsystem was added. DOE started funding the development of this system and it became known as Blue Gene/L (L for Light); development of the original Blue Gene system continued under the name Blue Gene/C (C for Cyclops) and, later, Cyclops64.

In November 2004 a 16-rack system, with each rack holding 1,024 compute nodes, achieved first place in the TOP500 list, with a Linpack performance of 70.72 TFLOPS.[1] It thereby overtook NEC's Earth Simulator, which had held the title of the fastest computer in the world since 2002. From 2004 through 2007 the Blue Gene/L installation at LLNL[6] gradually expanded to 104 racks, achieving 478 TFLOPS Linpack and 596 TFLOPS peak. The LLNL BlueGene/L installation held the first position in the TOP500 list for 3.5 years, until in June 2008 it was overtaken by IBM's Cell-based Roadrunner system at Los Alamos National Laboratory, which was the first system to surpass the 1 PetaFLOPS mark. The system was built in Rochester, MN IBM plant.

While the LLNL installation was the largest Blue Gene/L installation, many smaller installations followed. In November 2006, there were 27 computers on the TOP500 list using the Blue Gene/L architecture. All these computers were listed as having an architecture of eServer Blue Gene Solution. For example, three racks of Blue Gene/L were housed at the San Diego Supercomputer Center.

While the TOP500 measures performance on a single benchmark application, Linpack, Blue Gene/L also set records for performance on a wider set of applications. Blue Gene/L was the first supercomputer ever to run over 100 TFLOPS sustained on a real world application, namely a three-dimensional molecular dynamics code (ddcMD), simulating solidification (nucleation and growth processes) of molten metal under high pressure and temperature conditions. This achievement won the 2005 Gordon Bell Prize.

In June 2006, NNSA and IBM announced that Blue Gene/L achieved 207.3 TFLOPS on a quantum chemical application (Qbox).[7] At Supercomputing 2006,[8] Blue Gene/L was awarded the winning prize in all HPC Challenge Classes of awards.[9] In 2007, a team from the IBM Almaden Research Center and the University of Nevada ran an artificial neural network almost half as complex as the brain of a mouse for the equivalent of a second (the network was run at 1/10 of normal speed for 10 seconds).[10]

The Blue Gene/L supercomputer was unique in the following aspects:[11]

The Blue Gene/L architecture was an evolution of the QCDSP and QCDOC architectures. Each Blue Gene/L Compute or I/O node was a single ASIC with associated DRAM memory chips. The ASIC integrated two 700MHz PowerPC 440 embedded processors, each with a double-pipeline-double-precision Floating Point Unit (FPU), a cache sub-system with built-in DRAM controller and the logic to support multiple communication sub-systems. The dual FPUs gave each Blue Gene/L node a theoretical peak performance of 5.6 GFLOPS (gigaFLOPS). The two CPUs were not cache coherent with one another.

Read this article:

Blue Gene - Wikipedia, the free encyclopedia

IBM Roadrunner – Wikipedia, the free encyclopedia

IBM Roadrunner

Roadrunner components

Roadrunner was a supercomputer built by IBM for the Los Alamos National Laboratory in New Mexico, USA. The US$100-million Roadrunner was designed for a peak performance of 1.7 petaflops. It achieved 1.026 petaflops on May 25, 2008 to become the world's first TOP500 Linpack sustained 1.0 petaflops system.[2][3]

In November 2008, it reached a top performance of 1.456 petaflops, retaining its top spot in the TOP500 list.[4] It was also the fourth-most energy-efficient supercomputer in the world on the Supermicro Green500 list, with an operational rate of 444.94 megaflops per watt of power used. The hybrid Roadrunner design was then reused for several other energy efficient supercomputers.[5] Roadrunner was decommissioned by Los Alamos on March 31, 2013.[6] In its place, Los Alamos uses a supercomputer called Cielo, which was installed in 2010. Cielo is smaller and more energy efficient than Roadrunner, and cost $54 million.[6]

IBM built the computer for the U.S. Department of Energy's (DOE) National Nuclear Security Administration.[7][8] It was a hybrid design with 12,960 IBM PowerXCell 8i[9] and 6,480 AMD Opteron dual-core processors[10] in specially designed blade servers connected by Infiniband. The Roadrunner used Red Hat Enterprise Linux along with Fedora[11] as its operating systems and was managed with xCAT distributed computing software. It also used the Open MPI Message Passing Interface implementation.[12]

Roadrunner occupied approximately 296 server racks[13] which covered 560 square metres (6,000sqft)[14] and became operational in 2008. It was decommissioned March 31, 2013.[13] The DOE used the computer for simulating how nuclear materials age in order to predict whether the USA's aging arsenal of nuclear weapons are both safe and reliable. Other uses for the Roadrunner included the science, financial, automotive and aerospace industries.

Roadrunner differed from other contemporary supercomputers because it was the first hybrid supercomputer.[13] Previous supercomputers only used one processor architecture, since it was easier to design and program for. To realize the full potential of Roadrunner, all software had to be written specially for this hybrid architecture. The hybrid design consisted of dual-core Opteron server processors manufactured by AMD using the standard AMD64 architecture. Attached to each Opteron core is a PowerXCell 8i processor manufactured by IBM using Power Architecture and Cell technology. As a supercomputer, the Roadrunner was considered an Opteron cluster with Cell accelerators, as each node consists of a Cell attached to an Opteron core and the Opterons to each other.[15]

Roadrunner was in development from 2002 and went online in 2006. Due to its novel design and complexity it was constructed in three phases and became fully operational in 2008. Its predecessor was a machine also developed at Los Alamos named Dark Horse.[16] This machine was one of the earliest hybrid architecture systems originally based on ARM and then moved to the Cell processor. It was entirely a 3D design, its design integrated 3D memory, networking, processors and a number of other technologies.

The first phase of the Roadrunner was building a standard Opteron based cluster, while evaluating the feasibility to further construct and program the future hybrid version. This Phase 1 Roadrunner reached 71 teraflops and was in full operation at Los Alamos National Laboratory in 2006.

Phase 2 known as AAIS (Advanced Architecture Initial System) included building a small hybrid version of the finished system using an older version of the Cell processor. This phase was used to build prototype applications for the hybrid architecture. It went online in January 2007.

More:

IBM Roadrunner - Wikipedia, the free encyclopedia

macpro-AFPrelax-191213.jpg

December 19, 2013

The super-powerful desktop computer will go on sale today. - AFP/Relaxnews pic, December 19, 2013.The wait is over. Apple's super-sleek super-fast professional desktop will be launching in time for Christmas.

The fastest and most powerful personal computer in Apple's 37-year history will be going on sale today.

Apple has been teasing its design and features since June and promoting its endless scope for customisation.

And now, for $2999 (RM9,700), consumers will be able to snap up the "entry-level" model which boasts a 3.7GHz quad-core Intel Xeon E5 processor, two AMD FirePro D500 workstation GPUs (each one has 2GB of dedicated RAM) plus 256GB of on-board flash storage.

For $3999 (RM13,000) customers can upgrade all of that to 3.5GHz six-core processor, an extra 1GB of dedicated RAM for each graphics card, 16GB of RAM, but the same 265GB of flash storage.

But for those that need the ultimate in speed and performance and for whom money is no object, a 12-core processor, AMD FirePro D700 GPUs with 6GB of RAM and 64GB of system RAM can be specified, as can 1TB of flash storage. In other words, the computational equivalent of ordering a BMW. Just visit Apple's dedicated Mac Pro site.

Apple says that the computer will not just be available to order online from today, it can also be bought from its retail stores meaning that for some people it could be a very happy Christmas. But don't forget to buy a monitor, keyboard and mouse too, none of which are included as standard. - AFP/Relaxnews, December 19, 2013.

Visit link:

macpro-AFPrelax-191213.jpg

Supermicro® Expands Range of Energy Efficient VDI Server Solutions for NVIDIA GRID

- New Enterprise-Class GRID K1/K2 SuperServers Offer Customers More Configurations for Optimized Performance, Scalability and TCO

SAN JOSE, Calif., -- Super Micro Computer, Inc. (NASDAQ: SMCI), a global leader in high-performance, high-efficiency server, storage technology and green computing offers the industry's widest range of enterprise-class VDI server solutions optimized for NVIDIA GRID(TM) graphics-accelerated virtual desktops and applications. With high-performance virtual GPU technology enabling a new era in server-side computing, it is increasingly important to select platforms that provide optimal cooling alongside power-efficiency to maximize compute density and overall reliability. Supermicro's years of design and engineering expertise have yielded high-density GPU server platforms that offer the widest variety of flexible configurations in 1U, 2U, 4U/Tower, FatTwin(TM) and SuperBlade(R) computing solutions. The company's new NVIDIA GRID based server solutions take advantage of this to maximize user density and provide an uncompromised user experience in large scale virtualized environments. These application optimized systems deliver maximum productivity for Knowledge Workers and Power Users (GRID K1) or accelerated compute performance for Engineers and Designers (GRID K2). For a limited time (through January 31, 2014) and while supplies last*, Supermicro is offering a trial system discount on select NVIDIA GRID based VDI server solutions at http://www.supermicro.com/GRID_VDI. Additional systems supporting NVIDIA GRID K1/K2 include the new 4U 8x GPU SuperServer(R) (SYS-4027GR-TR) and 2x GPU SuperBlade(R) (SBI-7127RG-E( http://www.supermicro.com/products/superblade/module/SBI-7127RG-E.cfm )) supporting 20x GPUs + 20x CPUs per 7U.

"Supermicro provides Enterprise and Cloud Data Center customers with the best and widest range of energy efficient, performance optimized server solutions to help lower overall TCO and increase profit margins," said Charles Liang, President and CEO of Supermicro. "As computing resources and applications shift from office environments to the Data Center, IT experts that employ Supermicro systems like our high-density 1U 4x GPU SuperServer or cooling and resource optimized 4U FatTwin will win big. Our extensive selection of NVIDIA GRID certified platforms are exactly optimized for any scale application or virtualized workload, ensuring companies receive maximum performance per watt, per dollar, per square foot from their investment."

New NVIDIA GRID VDI Certified Systems:

1U SuperServers -- 2x Xeon E5-2680 V2, 16GB DDR3-1866, 2x Intel(R) 520 2.5" 240GB SATA 6Gb/s MLC SSD -- SYS-1027GR-TR2-NVK1 (1x K1) -- SYS-1027GR-TR2-NVK1 (1x K2) -- SYS-1027GR-TR2-2NVK1 (2x K1) -- SYS-1027GR-TR2-2NVK2 (2x K2)

2U SuperServers -- 2x Xeon E5-2680 V2, 16GB DDR3-1866, 2x Intel(R) 520 2.5" 240GB SATA 6Gb/s MLC SSD -- SYS-2027GR-TR-2NVK1 (1x K1) -- SYS-2027GR-TR-2NVK2 (2x K2) -- SYS-2027GR-TR-3NVK2 (3x K2)

4U/Tower Servers -- 2x Xeon E5-2680 V2, 16GB DDR3-1866, 2x Intel(R) 520 2.5" 240GB SATA 6Gb/s MLC SSD -- SYS-7047GR-TPRF-2NVK1 (2x K1) -- SYS-7047GR-TPRF-2NVK2 (2x K2) -- SYS-7047GR-TPRF-3NVK2 (3x K2)

4U 4-Node FatTwin(TM) SuperServers -- (each node) 2x Xeon E5-2680 V2, 1x K1 or K2 GPU, 16GB DDR3-1866, 2x Intel(R) 2.5" 520 240GB SATA 6Gb/s MLC SSD -- SYS-F627G2-FT+-NVK1 (4x K1) -- SYS-F627G2-FT+-NVK2 (4x K2)

*Visit http://www.supermicro.com/GRID_VDI for complete information on Supermicro's NVIDIA GRID based solutions and Terms and Conditions for the special limited time GRID system trial offer.

Follow Supermicro on Facebook( https://www.facebook.com/Supermicro ) and Twitter( http://twitter.com/Supermicro_SMCI ) to receive their latest news and announcements.

Go here to read the rest:

Supermicro® Expands Range of Energy Efficient VDI Server Solutions for NVIDIA GRID

Stem Cell Therapy – Facet Syndrome Patients Relieve Back and Neck Pain Dr Robert Wagner – NSPC – Video


Stem Cell Therapy - Facet Syndrome Patients Relieve Back and Neck Pain Dr Robert Wagner - NSPC
How to know if the cause of your back or neck pain is Facet Syndrome. Discover how biologic regenerative treatments are able to pick up where traditional tre...

By: StemCell Arts

Excerpt from:

Stem Cell Therapy - Facet Syndrome Patients Relieve Back and Neck Pain Dr Robert Wagner - NSPC - Video

Stem cell – Wikipedia, the free encyclopedia

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. They are found in multicellular organisms. In mammals, there are two broad types of stem cells: embryonic stem cells, which are isolated from the inner cell mass of blastocysts, and adult stem cells, which are found in various tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing adult tissues. In a developing embryo, stem cells can differentiate into all the specialized cellsectoderm, endoderm and mesoderm (see induced pluripotent stem cells)but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues.

There are three accessible sources of autologous adult stem cells in humans:

Stem cells can also be taken from umbilical cord blood just after birth. Of all stem cell types, autologous harvesting involves the least risk. By definition, autologous cells are obtained from one's own body, just as one may bank his or her own blood for elective surgical procedures.

Adult stem cells are routinely used in medical therapies, for example in bone marrow transplantation. Stem cells can now be artificially grown and transformed (differentiated) into specialized cell types with characteristics consistent with cells of various tissues such as muscles or nerves. Embryonic cell lines and autologous embryonic stem cells generated through therapeutic cloning have also been proposed as promising candidates for future therapies.[1] Research into stem cells grew out of findings by Ernest A. McCulloch and James E. Till at the University of Toronto in the 1960s.[2][3]

The classical definition of a stem cell requires that it possess two properties:

Two mechanisms exist to ensure that a stem cell population is maintained:

Potency specifies the differentiation potential (the potential to differentiate into different cell types) of the stem cell.[4]

In practice, stem cells are identified by whether they can regenerate tissue. For example, the defining test for bone marrow or hematopoietic stem cells (HSCs) is the ability to transplant the cells and save an individual without HSCs. This demonstrates that the cells can produce new blood cells over a long term. It should also be possible to isolate stem cells from the transplanted individual, which can themselves be transplanted into another individual without HSCs, demonstrating that the stem cell was able to self-renew.

Properties of stem cells can be illustrated in vitro, using methods such as clonogenic assays, in which single cells are assessed for their ability to differentiate and self-renew.[7][8] Stem cells can also be isolated by their possession of a distinctive set of cell surface markers. However, in vitro culture conditions can alter the behavior of cells, making it unclear whether the cells will behave in a similar manner in vivo. There is considerable debate as to whether some proposed adult cell populations are truly stem cells.

Embryonic stem (ES) cells are stem cells derived from the inner cell mass of a blastocyst, an early-stage embryo.[9] Human embryos reach the blastocyst stage 45 days post fertilization, at which time they consist of 50150 cells. ES cells are pluripotent and give rise during development to all derivatives of the three primary germ layers: ectoderm, endoderm and mesoderm. In other words, they can develop into each of the more than 200 cell types of the adult body when given sufficient and necessary stimulation for a specific cell type. They do not contribute to the extra-embryonic membranes or the placenta.

Here is the original post:

Stem cell - Wikipedia, the free encyclopedia

Stem cell therapy – Wikipedia, the free encyclopedia

This article is about the medical therapy. For the cell type, see Stem cell.

Stem cell therapy is an intervention strategy that introduces new adult stem cells into damaged tissue in order to treat disease or injury. Many medical researchers believe that stem cell treatments have the potential to change the face of human disease and alleviate suffering.[1] The ability of stem cells to self-renew and give rise to subsequent generations with variable degrees of differentiation capacities,[2] offers significant potential for generation of tissues that can potentially replace diseased and damaged areas in the body, with minimal risk of rejection and side effects.

A number of stem cell therapies exist, but most are at experimental stages, costly or controversial,[3] with the notable exception of bone-marrow transplantation.[4] Medical researchers anticipate that adult and embryonic stem cells will soon be able to treat cancer, Type 1 diabetes mellitus, Parkinson's disease, Huntington's disease, Celiac disease, cardiac failure, muscle damage and neurological disorders, and many others.[5] Nevertheless, before stem cell therapeutics can be applied in the clinical setting, more research is necessary to understand stem cell behavior upon transplantation as well as the mechanisms of stem cell interaction with the diseased/injured microenvironment.[5]

For over 30 years, bone-marrow, and more recently, umbilical-cord blood stem cells, have been used to treat cancer patients with conditions such as leukaemia and lymphoma.[6][7] During chemotherapy, most growing cells are killed by the cytotoxic agents. These agents, however, cannot discriminate between the leukaemia or neoplastic cells, and the hematopoietic stem cells within the bone marrow. It is this side effect of conventional chemotherapy strategies that the stem cell transplant attempts to reverse; a donor's healthy bone marrow reintroduces functional stem cells to replace the cells lost in the host's body during treatment.

Stroke and traumatic brain injury lead to cell death, characterized by a loss of neurons and oligodendrocytes within the brain. Healthy adult brains contain neural stem cells which divide to maintain general stem cell numbers, or become progenitor cells. In healthy adult animals, progenitor cells migrate within the brain and function primarily to maintain neuron populations for olfaction (the sense of smell). In pregnancy and after injury, this system appears to be regulated by growth factors and can increase the rate at which new brain matter is formed.[citation needed] Although the reparative process appears to initiate following trauma to the brain, substantial recovery is rarely observed in adults, suggesting a lack of robustness.[8]

Stem cells may also be used to treat brain degeneration, such as in Parkinson's and Alzheimer's disease.[9][10]

Pharmacological activation of an endogenous population of neural stem cells / neural precursor cells by soluble factors has been reported to induce powerful neuroprotection and behavioral recovery in adult rat models of neurological disorder through a signal transduction pathway involving the phosphorylation of STAT3 on the serine residue and subsequent Hes3 expression increase (STAT3-Ser/Hes3 Signaling Axis).[11][12][13]

Stem cell technology gives hope of effective treatment for a variety of malignant and non-malignant diseases through the rapid developing field that combines the efforts of cell biologists, geneticists and clinicians. Stem cells are defined as totipotent progenitor cells capable of self-renewal and multi-lineage differentiation. Stem cells survive well and show steady division in culture which then causes them the ideal targets for vitro manipulation. Research into solid tissue stem cells has not made the same progress as haematopoietic stem cells because of the difficulty of reproducing the necessary and precise 3D arrangements and tight cell-cell and cell-extracellular matrix interactions that exist in solid organs. Yet, the ability of tissue stem cells to assimilate into the tissue cytoarchitecture under the control of the host microenvironment and developmental cues, makes them ideal for cell replacement therapy. [3] [14]

The development of gene therapy strategies for treatment of intra-cranial tumours offers much promise, and has shown to be successful in the treatment of some dogs;[15] although research in this area is still at an early stage. Using conventional techniques, brain cancer is difficult to treat because it spreads so rapidly. Researchers at the Harvard Medical School transplanted human neural stem cells into the brain of rodents that received intracranial tumours. Within days, the cells migrated into the cancerous area and produced cytosine deaminase, an enzyme that converts a non-toxic pro-drug into a chemotheraputic agent. As a result, the injected substance was able to reduce the tumor mass by 81 percent. The stem cells neither differentiated nor turned tumorigenic.[16]

Some researchers believe that the key to finding a cure for cancer is to inhibit proliferation of cancer stem cells. Accordingly, current cancer treatments are designed to kill cancer cells. However, conventional chemotherapy treatments cannot discriminate between cancerous cells and others. Stem cell therapies may serve as potential treatments for cancer.[17] Research on treating lymphoma using adult stem cells is underway and has had human trials. Essentially, chemotherapy is used to completely destroy the patients own lymphocytes, and stem cells injected, eventually replacing the immune system of the patient with that of the healthy donor.

See original here:

Stem cell therapy - Wikipedia, the free encyclopedia

Stem Cell Therapy Research Dr. Steenblock Umbilical Cord Stem …

We stand at the threshold of a new and exciting medicine of Regeneration where transplants of stem cells can potentially restore function to injured, diseased and debilitated tissues and organs.

Embryonic-like stem cells found in umbilical cord blood!

Umbilical cord blood was first used for blood and immune system disorders about 18 years ago.For the past several years, new possibilities for their use in a wider variety of health conditions, genetic disorders and anti-aging treatmentshave beengaining support with various multipotent stem cells and progenitor cells being discovered in the cord blood. In fact, embryonic-like stem cells have actually been found in umbilical cord blood and are beingused in clinical researchnow for various neurological disorders outside the United States. Dr. Colin McGuckin and associates from the U.K. have published preliminary findings on these embryonic-like stem cells.

Whether the health challenge is Alzheimer's Disease, Stroke, Traumatic Brain Injury, Cerebral Palsy, Spinal Cord Injuries, Parkinson's Disease, Heart Disease, Diabetes, Blindness or Immune Deficiencies, the results of preliminary animal and human studies have been very promising.

With each passing year, the field is growing exponentially and we invite you to find out more about this exciting new field of regenerative medicine.

This website is sponsored by the Steenblock Research Institute, a 501(c)(3)California non-profit corporation dedicated to educating the public about safe and effective alternatives for difficult medical cases. Contribute to our on-going projects in researching medical alternatives here.

UMBILICAL CORD STEM CELL THERAPY by David Steenblock, D.O. and Anthony Payne, Ph.D.

This book presents case studies of umbilical cord stem cells being used to treat patients with cancer, cerebral palsy, stroke, ALS, MS and other challenging medical conditions.

Read the original here:

Stem Cell Therapy Research Dr. Steenblock Umbilical Cord Stem ...

Mayo cell therapy researcher plans to grow stem cells in space, where he thinks they will grow faster than on Earth

Abba Zubair, medical and scientific director of the Cell Therapy Laboratory at the Mayo Clinic in Jacksonville, wants to test the feasibility of growing stem cells in outer space, cells that could be used to generate new tissue and even new organs in human beings.

There are reasons to believe that stem cells, which are hard to grow in the great quantity they are needed on Earth, will grow much more rapidly in the microgravity environment in space, Zubair thinks. Now the Center for the Advancement in Science in Space has given Zubair a $300,000 grant to test that by placing stem cells in a specialized cell bioreactor in the International Space Station.

It now takes a month to generate enough cells for a few patients, Zubair said. A clinical laboratory in space could provide the answer we all have been seeking for regenerative medicine. ... If you have a ready supply of these cells, you can treat almost any condition and can theoretically regenerate entire organs using a scaffold. Additionally, they dont need to come from individual patients. Anyone can use them without rejection.

The stem cells he plans to grow in space will be stem cells that can induce regeneration of neurons and blood vessels in patients who have suffered hemorrhagic strokes caused by blood clots.

I have a special personal interest in stroke, Zubair said. Thats what killed my mom years ago. I really would like to conquer and treat stroke.

The first step in growing stem cells in space is happening at the University of Colorado where engineers are building the cell bioreactor Zubair will use on the space station. Within a year, Zubair hopes to transport the bioreactor and stem cells to the space station, perhaps aboard a flight by SpaceX, a company expected to begin commercial flights to the space station soon.

Once the bioreactor and stem cells are aboard the space station, it will take about a month to grow them, Zubair said. The results will then be analyzed by the astronauts on the space station and by researches back in Zubairs Jacksonville laboratories.

We will be trying to determine if our notion that stem cells grow faster in microgravity is true, Zubair said. We also want to know how feasible it is to produce clinical grade cells in space that can be used in humans.

Hes optimistic his study will show that growing stem cells in space is a viable way to create stem cells in quantity.

Were quite excited, he said. I really think the future is full of promise. We just have to take the opportunity to make that a reality.

See more here:

Mayo cell therapy researcher plans to grow stem cells in space, where he thinks they will grow faster than on Earth

Bone Marrow Transplantation and Peripheral Blood Stem Cell …

What are bone marrow and hematopoietic stem cells?

Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic or blood-forming stem cells. (Hematopoietic stem cells are different from embryonic stem cells. Embryonic stem cells can develop into every type of cell in the body.) Hematopoietic stem cells divide to form more blood-forming stem cells, or they mature into one of three types of blood cells: white blood cells, which fight infection; red blood cells, which carry oxygen; and platelets, which help the blood to clot. Most hematopoietic stem cells are found in the bone marrow, but some cells, called peripheral blood stem cells (PBSCs), are found in the bloodstream. Blood in the umbilical cord also contains hematopoietic stem cells. Cells from any of these sources can be used in transplants.

What are bone marrow transplantation and peripheral blood stem cell transplantation?

Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy. There are three types of transplants:

Why are BMT and PBSCT used in cancer treatment?

One reason BMT and PBSCT are used in cancer treatment is to make it possible for patients to receive very high doses of chemotherapy and/or radiation therapy. To understand more about why BMT and PBSCT are used, it is helpful to understand how chemotherapy and radiation therapy work.

Chemotherapy and radiation therapy generally affect cells that divide rapidly. They are used to treat cancer because cancer cells divide more often than most healthy cells. However, because bone marrow cells also divide frequently, high-dose treatments can severely damage or destroy the patients bone marrow. Without healthy bone marrow, the patient is no longer able to make the blood cells needed to carry oxygen, fight infection, and prevent bleeding. BMT and PBSCT replace stem cells destroyed by treatment. The healthy, transplanted stem cells can restore the bone marrows ability to produce the blood cells the patient needs.

In some types of leukemia, the graft-versus-tumor (GVT) effect that occurs after allogeneic BMT and PBSCT is crucial to the effectiveness of the treatment. GVT occurs when white blood cells from the donor (the graft) identify the cancer cells that remain in the patients body after the chemotherapy and/or radiation therapy (the tumor) as foreign and attack them. (A potential complication of allogeneic transplants called graft-versus-host disease is discussed in Questions 5 and 14.)

What types of cancer are treated with BMT and PBSCT?

BMT and PBSCT are most commonly used in the treatment of leukemia and lymphoma. They are most effective when the leukemia or lymphoma is in remission (the signs and symptoms of cancer have disappeared). BMT and PBSCT are also used to treat other cancers such as neuroblastoma (cancer that arises in immature nerve cells and affects mostly infants and children) and multiple myeloma. Researchers are evaluating BMT and PBSCT in clinical trials (research studies) for the treatment of various types of cancer.

Continue reading here:

Bone Marrow Transplantation and Peripheral Blood Stem Cell ...

Stem-Cell Therapy and Repair after Heart Attack and Heart Failure

Stem Cell Therapy: Helping the Body Heal Itself

Stem cells are natures own transformers. When the body is injured, stem cells travel the scene of the accident. Some come from the bone marrow, a modest number of others, from the heart itself. Additionally, theyre not all the same. There, they may help heal damaged tissue. They do this by secreting local hormones to rescue damaged heart cells and occasionally turning into heart muscle cells themselves. Stem cells do a fairly good job. But they could do better for some reason, the heart stops signaling for heart cells after only a week or so after the damage has occurred, leaving the repair job mostly undone. The partially repaired tissue becomes a burden to the heart, forcing it to work harder and less efficiently, leading to heart failure.

Initial research used a patients own stem cells, derived from the bone marrow, mainly because they were readily available and had worked in animal studies. Careful study revealed only a very modest benefit, so researchers have moved on to evaluate more promising approaches, including:

No matter what you may read, stem cell therapy for damaged hearts has yet to be proven fully safe and beneficial. It is important to know that many patients are not receiving the most current and optimal therapies available for their heart failure. If you have heart failure, and wondering about treatment options, an evaluation or a second opinion at a Center of Excellence can be worthwhile.

Randomized clinical trials evaluating these different approaches typically allow enrollment of only a few patients from each hospital, and hence what may be available at the Cleveland Clinic varies from time to time. To inquire about current trials, please call 866-289-6911 and speak to our Resource Nurses.

Cleveland Clinic is a large referral center for advanced heart disease and heart failure we offer a wide range of therapies including medications, devices and surgery. Patients will be evaluated for the treatments that best address their condition. Whether patients meet the criteria for stem cell therapy or not, they will be offered the most advanced array of treatment options.

Reviewed: 04/13

Continued here:

Stem-Cell Therapy and Repair after Heart Attack and Heart Failure

Stem Cell Therapy by Vet-Stem, a Surprising Alternative to Hip Surgery for a New Jersey Chocolate Labrador Retriever

Poway, CA (PRWEB) December 19, 2013

Amazing Grace Hamiltons banked stem cells from Vet-Stem, Inc. have recently helped her avoid hip surgery for the second time. Gracie is now nearly 12 years old and her owners noticed her activities had dramatically slowed in the last year. They turned to banked stem cells that Gracie had stored with Vet-Stem, Inc. in Poway, California to help with the discomfort and pain of arthritis that was slowing her down.

When Gracies owners brought her to Garden State Veterinary Specialists in Tinton Falls, New Jersey in October of this year the x-rays showed a severely deteriorated right hip. Dr. Thomas Scavelli and Dr. Michael Hoelzler were very concerned and recommended hip replacement. Gracies owners wanted to try stem cell therapy first, since it had given them such positive results five years before.

We needed to give the stem cells a try before going to the more invasive surgical approach, Mrs. Hamilton said. At the time of the procedure Dr. Hoelzler told me that Gracies hips were the worst he had seen, but in just a couple of days after the stem cell therapy we began to see a difference. Just shy of two weeks after the procedure I took her back to Dr. Hoelzler and he was very impressed. She was walking comfortably.

At three years Gracie had been diagnosed with hip dysplasia. By six years of age she had slowed to the point of great concern as her owners described it. The pain caused by arthritis from the hip dysplasia was beginning to interfere with her life.

Gracie was no longer running and jumping, and certain activities had become difficult (like climbing onto my husbands sailboat). She also had a noticeable limp, Mrs. Hamilton remembered the signs of pain and discomfort that prompted Gracies first stem cell therapy five years before.

Gracie was brought to Dr. Scavelli in 2008 with painful symptoms, and stem cell therapy for pets was the latest, cutting edge treatment. Gracies owners understood that without stem cell therapy Gracie would have faced hip surgery at the time.

We are grateful for stem cell therapy which has restored Gracies ability to enjoy her morning walks again, Mrs. Hamilton shared, She enjoys wrestling with us and playing with her toys. She looks forward to visiting her friends, and prances around like a puppy. Gracie is a happy dog and we are happy owners because she does not appear to be in pain anymore!

About Vet-Stem, Inc.

Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

See the original post here:

Stem Cell Therapy by Vet-Stem, a Surprising Alternative to Hip Surgery for a New Jersey Chocolate Labrador Retriever

Will stem cell therapy help cure spinal cord injury?

Dec. 17, 2013 A systematic survey of the scientific literature shows that stem cell therapy can have a statistically significant impact on animal models of spinal cord injury, and points the way for future studies.

Spinal cord injuries are mostly caused by trauma, often incurred in road traffic or sporting incidents, often with devastating and irreversible consequences, and unfortunately having a relatively high prevalence (250,000 patients in the USA; 80% of cases are male). High-profile campaigners like the late actor Christopher Reeve, himself a victim of sports-related spinal cord injury, have placed high hopes in stem cell transplantation. But how likely is it to work?

This question is addressed in a paper published 17th December in the open access journal PLOS Biology by Ana Antonic, David Howells and colleagues from the Florey Institute and the University of Melbourne, Australia, and Malcolm MacLeod and colleagues from the University of Edinburgh, UK.

Stem cell therapy aims to use special regenerative cells (stem cells) to repopulate areas of damage that result from spinal cord injuries, with the hope of improving the ability to move ("motor outcomes") and to feel ("sensory outcomes") beyond the site of the injury. Many studies have been performed that involve animal models of spinal cord injury (mostly rats and mice), but these are limited in scale by financial, practical and ethical considerations. These limitations hamper each individual study's statistical power to detect the true effects of the stem cell implantation.

This new study gets round this problem by conducting a "meta-analysis" -- a sophisticated and systematic cumulative statistical reappraisal of many previous laboratory experiments. In this case the authors assessed 156 published studies that examined the effects of stem cell treatment for experimental spinal injury in a total of about 6000 animals.

Overall, they found that stem cell treatment results in an average improvement of about 25% over the post-injury performance in both sensory and motor outcomes, though the results can vary widely between animals. For sensory outcomes the degree of improvement tended to increase with the number of cells introduced -- scientists are often reassured by this sort of "dose response," as it suggests a real underlying biologically plausible effect.

The authors went on to use their analysis to explore the effects of bias (whether the experimenters knew which animals were treated and which untreated), the way that the stem cells were cultured, the way that the spinal injury was generated, and the way that outcomes were measured. In each case, important lessons were learned that should help inform and refine the design of future animal studies. The meta-analysis also revealed some surprises that should provoke further investigation -- there was little evidence of any beneficial sensory effects in female animals, for example, and it didn't seem to matter whether immunosuppressive drugs were administered or not.

The authors conclude: "Extensive recent preclinical literature suggests that stem cell-based therapies may offer promise; however the impact of compromised internal validity and publication bias means that efficacy is likely to be somewhat lower than reported here."

Read more from the original source:

Will stem cell therapy help cure spinal cord injury?